Plain-English translation of NCT06832228 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether pomalidomide works better when combined with two other medications (rituximab and an anti-PD-1 antibody) for people with advanced diffuse large B-cell lymphoma who haven't responded to, or have relapsed after, earlier treatments. The study will enroll 30 patients and follow them through multiple cycles of the medication to see how well it works and how safe it is.
Most patients with this type of lymphoma eventually stop responding to standard treatments, and doctors need new options for those who have already tried two or more previous therapies. This trial is exploring whether combining these three medications together might help patients who are running out of other options.
You likely qualify if…
You likely don't qualify if…
You would receive four to six cycles of the treatment, with each cycle lasting 28 days. During each cycle, you would take one medication by mouth daily for 21 days, and receive the other two medications through injections or infusions on the first day. If your lymphoma responds well to the treatment, you may continue with maintenance therapy (lower doses) for one to two years. The study team will monitor you closely with blood tests and scans to track how well the treatment is working and watch for any side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China
Sponsor
Zhejiang Cancer Hospital
Enrollment target
~30 participants
Started
September 2024
Primary completion
September 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in February 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Haifeng Yu, MD
Zhejiang Cancer Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.